Skip to main content

Adverse Effects of Fenofibrate in Mice Deficient in the Protein Quality Control Regulator, CHIP.

Publication ,  Journal Article
Ravi, S; Parry, TL; Willis, MS; Lockyer, P; Patterson, C; Bain, JR; Stevens, RD; Ilkayeva, OR; Newgard, CB; Schisler, JC
Published in: J Cardiovasc Dev Dis
August 15, 2018

We previously reported how the loss of CHIP expression (Carboxyl terminus of Hsc70-Interacting Protein) during pressure overload resulted in robust cardiac dysfunction, which was accompanied by a failure to maintain ATP levels in the face of increased energy demand. In this study, we analyzed the cardiac metabolome after seven days of pressure overload and found an increase in long-chain and medium-chain fatty acid metabolites in wild-type hearts. This response was attenuated in mice that lack expression of CHIP (CHIP-/-). These findings suggest that CHIP may play an essential role in regulating oxidative metabolism pathways that are regulated, in part, by the nuclear receptor PPARα (Peroxisome Proliferator-Activated Receptor alpha). Next, we challenged CHIP-/- mice with the PPARα agonist called fenofibrate. We found that treating CHIP-/- mice with fenofibrate for five weeks under non-pressure overload conditions resulted in decreased skeletal muscle mass, compared to wild-type mice, and a marked increase in cardiac fibrosis accompanied by a decrease in cardiac function. Fenofibrate resulted in decreased mitochondrial cristae density in CHIP-/- hearts as well as decreased expression of genes involved in the initiation of autophagy and mitophagy, which suggests that a metabolic challenge, in the absence of CHIP expression, impacts pathways that contribute to mitochondrial quality control. In conclusion, in the absence of functional CHIP expression, fenofibrate results in unexpected skeletal muscle and cardiac pathologies. These findings are particularly relevant to patients harboring loss-of-function mutations in CHIP and are consistent with a prominent role for CHIP in regulating cardiac metabolism.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Cardiovasc Dev Dis

DOI

EISSN

2308-3425

Publication Date

August 15, 2018

Volume

5

Issue

3

Location

Switzerland

Related Subject Headings

  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ravi, S., Parry, T. L., Willis, M. S., Lockyer, P., Patterson, C., Bain, J. R., … Schisler, J. C. (2018). Adverse Effects of Fenofibrate in Mice Deficient in the Protein Quality Control Regulator, CHIP. J Cardiovasc Dev Dis, 5(3). https://doi.org/10.3390/jcdd5030043
Ravi, Saranya, Traci L. Parry, Monte S. Willis, Pamela Lockyer, Cam Patterson, James R. Bain, Robert D. Stevens, Olga R. Ilkayeva, Christopher B. Newgard, and Jonathan C. Schisler. “Adverse Effects of Fenofibrate in Mice Deficient in the Protein Quality Control Regulator, CHIP.J Cardiovasc Dev Dis 5, no. 3 (August 15, 2018). https://doi.org/10.3390/jcdd5030043.
Ravi S, Parry TL, Willis MS, Lockyer P, Patterson C, Bain JR, et al. Adverse Effects of Fenofibrate in Mice Deficient in the Protein Quality Control Regulator, CHIP. J Cardiovasc Dev Dis. 2018 Aug 15;5(3).
Ravi, Saranya, et al. “Adverse Effects of Fenofibrate in Mice Deficient in the Protein Quality Control Regulator, CHIP.J Cardiovasc Dev Dis, vol. 5, no. 3, Aug. 2018. Pubmed, doi:10.3390/jcdd5030043.
Ravi S, Parry TL, Willis MS, Lockyer P, Patterson C, Bain JR, Stevens RD, Ilkayeva OR, Newgard CB, Schisler JC. Adverse Effects of Fenofibrate in Mice Deficient in the Protein Quality Control Regulator, CHIP. J Cardiovasc Dev Dis. 2018 Aug 15;5(3).

Published In

J Cardiovasc Dev Dis

DOI

EISSN

2308-3425

Publication Date

August 15, 2018

Volume

5

Issue

3

Location

Switzerland

Related Subject Headings

  • 3201 Cardiovascular medicine and haematology